$BXP

Evercore ISI Adjusts Price Target on BXP to $67 From $71, Keeps In Line Rating

Evercore ISI reduced its price target for BXP from $71 to $67, maintaining an 'In Line' rating. Scotiabank also lowered its target from $76 to $73, keeping a 'Sector Outperform' rating. BXP's stock price was $63.17, down 1.19%.

Original reporting
Published Sep 21, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BXP
Bearish
medium confidence
Mentioned
$BXP
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$BXPBearishMed
01

Why it matters

The downgrade may trigger short‑term selling pressure and could influence other analysts' views.

02

Market read

Analyst price‑target changes are a key driver for REIT valuations and can affect sector sentiment.

03

What to watch

Potential upside from upcoming capital projects and a rebound in office demand post‑pandemic.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

Evercore ISI regularly updates price targets based on valuation, EPS revisions, and visibility metrics.

Company-level read

Ticker impact

$BXPBearishMedium confidence
Context

Evercore ISI lowered its price target for Boston Properties to $67 from $71, indicating a bearish outlook.

Expected impact

Potential 2‑3% downside over the next few days.

Evidence & confidence

Price target cuts often precede sell pressure, especially when the target is reduced by 6%.

Market effects

May signal broader concerns in the REIT sector, especially office properties.

Limited to U.S. office REITs, no immediate global effect.

Low, confined to U.S. real‑estate investors.

Counterpoint

The target cut could be overly cautious if recent lease renewals exceed expectations.

Key entities

  • Evercore ISI

    Equity research firm providing the price target revision.

  • Boston Properties

    U.S. REIT focused on office properties, ticker BXP.

Related articles

$BXPMedAI 8/10

Did BXP’s (BXP) Upbeat Q2 Beat and Higher FFO Outlook Just Shift Its Investment Narrative?

BXP reported Q2 2026 earnings exceeding expectations and raised its full-year FFO outlook, citing improved business fundamentals. The company's investment narrative hinges on high-quality office and life science space in key markets, with risks tied to new developments and leasing. BXP's $1.2B construction loan for 343 Madison Avenue highlights both potential and risks. Analysts' earnings estimates for 2029 range from $290.1M to $343.6M, with revenue projections between $3.7B and $3.8B.

$BXPMedAI 8/10

BXP's $1.2 Billion 343 Madison Loan Advances a Major Growth Project

BXP closed a $1.2B loan for its $2B 343 Madison Ave project, reducing equity needs to $341M. The 4-year loan at Term SOFR + 2.50% (declining to +2.25% upon milestones) funds 60% of costs. BXP targets 7.5%-8% returns, pending leasing and construction progress. The project is 50% pre-leased, with delivery expected in late 2029.

$BXPMed

BXP, Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics BXP delivered a strong second quarter, exceeding FFO guidance by $0.08 and raising the 2026 midpoint by $0.05, driven by faster-than-expected leasing and occupancy gains. Management attributes the leasing momentum to a 'very healthy environment' for premier workplaces, noting that AI is acting as a significant tailwind by driving space expansions and upgrades among tech and professional service firms.

$BXPMed

BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer

BXP announced it secured a $1.2B construction loan for its 930,000 sq ft, 46-story office tower at 343 Madison Ave in Midtown, with a four-year term plus a one-year extension option, from Wells Fargo, Bank of America Securities, BNY Mellon and J.P. Morgan. Completion is set for 2029; the project is 50% pre-leased. BXP reported Q2 2026 FFO of $283.4M ($1.78/share) and revenue of $895.7M.

$BXPMed

BXP Selling 7 Times Square Ground Lease

Boston Properties (BXP) is marketing the 7 Times Square ground lease via Eastdil Secured, hiring Will Silverman and Gary Phillips. BXP expects proceeds of $700 million to $750 million, with bids due soon. The 1.2M sq ft tower has a 99-year lease and is 91% occupied. The deal would test Times Square office demand.

$BXPMed

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC (AIM: BXP) reported unaudited Q3 and nine-month results ended 31 March 2026. For nine months, net sales rose 13.1% to BDT 41,428.0m (£256.9m) and profit after tax increased 34.0% to BDT 7,048.6m (£43.7m). In Q3, net sales grew 8.1% to BDT 13,627.8m (£84.5m) and PAT rose 30.6% to BDT 2,254.4m (£14.0m).